Azeliragon in MGMT Unmethylated Glioblastoma

Exclusion criteria

• ✕. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free or not requiring active therapy for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible).
• ✕. Prior cranial RT or RT to the head and neck where potential field overlap may exist.
• ✕. Prior use of carmustine (Gliadel) wafers or any other intratumoral or intracavitary treatment.
• ✕. Recurrent or multicentric disease. Multicentric disease is defined as multiple discrete areas of tumor without connecting T2 signal abnormality.
• ✕. Infratentorial disease or metastatic disease beyond the brain.
• ✕. Known IDH mutation. IDH status could be determined by either immunohistochemistry or sequencing as evaluated per routine clinical care.
• ✕. Patients with a serious active infection (such as a wound infection requiring parenteral antibiotics) at the time of study entry or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment
• ✕. Patients with any condition (e.g., psychological, geographical, etc.) that does not permit compliance with the protocol.